Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + tamoxifen
- Development stage
- Unknown
- Lead developer
- Centre Léon Bérard
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Everolimus + tamoxifen is a combination therapy that pairs an mTOR inhibitor (everolimus) with a selective estrogen receptor modulator (tamoxifen). This combination has shown efficacy in treating hormone receptor-positive, HER2-negative metastatic breast cancer that has developed resistance to aromatase inhibitors. The addition of everolimus helps overcome endocrine resistance by inhibiting the mTOR pathway, which is often activated in hormone-resistant breast cancer.
02
Targets
FKBP1AmTOR (Mammalian target of rapamycin kinase)ER (Estrogen receptor)
Beyond the preview
Go deeper on everolimus + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + tamoxifen.